Webinar Date/Time: Thursday, September 7th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
This webinar will address global oncology trends and how they impact sponsors preparing for early phase oncology trials.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/global-oncology
Event Overview:
Global oncology R&D continues to expand, bringing exciting new treatment options to patients. Seventy percent of the R&D pipeline is driven by the innovation of biotech companies. This creates immense pressure to deliver novel treatments and secure investor funding in a highly complex environment.
Join this webinar to hear from experts with the IQVIA Institute and IQVIA Biotech about global oncology trends impacting sponsors and how to optimize clinical trial strategy.
Three key take-aways
Speakers:
Murray Aitken
Executive Director
IQVIA Institute for Human Data Science
As head of the IQVIA Institute for Human Data Science, Murray Aitken provides policy setters and decision-makers in the global health sector with evidence, analysis, and insights that contribute to the advancement of Human Data Science to improve human health outcomes.
Murray is tasked with creating and managing a research agenda that leaders in global governments, payers, providers, academia, and the life sciences industry use to accelerate the understanding of global trends in disease patterns, data science, and technology. This research is used to foster innovation critical to evidence-based decision-making and the advancement of human health.
He holds an MBA, with distinction, from Harvard University and a Master of Commerce from the University of Auckland in New Zealand.
Gerhard Du Toit
Global Oncology Head
IQVIA Biotech
As Global Head of Oncology, Gerhard Du Toit oversees all aspects of clinical project management to optimize strategic plans and enhance delivery for early and late phase oncology clinical trials. He is committed to delivering compliant, expeditious, ethical solutions that respect patient safety, meet GCP requirements, and add value to the needs of oncology customers. Working for several global clinical research organizations in his career, Gerhard is a seasoned healthcare executive with more than 25 years of experience in project, clinical and data management, business development and statistics.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/global-oncology
Tremfya Shows Superior Endoscopic Remission Rates in Crohn Disease, Ulcerative Colitis
October 11th 2024Tremfya (guselkumab) demonstrated superior endoscopic remission rates in both Crohn disease and ulcerative colitis, including biologic-naïve and biologic-refractory patients, according to Phase III clinical trial data.
Tulisokibart Shows Superior Efficacy in Achieving Clinical Remission for Ulcerative Colitis Patients
October 2nd 2024Proof-of-concept Phase II ARTEMIS-UC trial shows efficacy of investigational humanized monoclonal antibody tulisokibart in treating inflammatory bowel disease compared with placebo.